181 related articles for article (PubMed ID: 15492852)
21. Expression of p53 family genes in urinary bladder cancer: correlation with disease aggressiveness and recurrence.
Papadogianni D; Soulitzis N; Delakas D; Spandidos DA
Tumour Biol; 2014 Mar; 35(3):2481-9. PubMed ID: 24213852
[TBL] [Abstract][Full Text] [Related]
22. CpG island methylation in Schistosoma- and non-Schistosoma-associated bladder cancer.
Gutiérrez MI; Siraj AK; Khaled H; Koon N; El-Rifai W; Bhatia K
Mod Pathol; 2004 Oct; 17(10):1268-74. PubMed ID: 15154012
[TBL] [Abstract][Full Text] [Related]
23. p53 activation in chronic radiation-treated breast cancer cells: regulation of MDM2/p14ARF.
Xia L; Paik A; Li JJ
Cancer Res; 2004 Jan; 64(1):221-8. PubMed ID: 14729628
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic regulation of vascular endothelial growth factor a dynamic expression in transitional cell carcinoma.
Ping SY; Shen KH; Yu DS
Mol Carcinog; 2013 Jul; 52(7):568-79. PubMed ID: 22392726
[TBL] [Abstract][Full Text] [Related]
25. Different expression of P14ARF defines two groups of breast carcinomas in terms of TP73 expression and TP53 mutational status.
Domínguez G; Silva J; Silva JM; García JM; Larrondo FJ; Vargas J; Sanfrutos L; Provencio M; España P; Bonilla F
Genes Chromosomes Cancer; 2001 Jun; 31(2):99-106. PubMed ID: 11319797
[TBL] [Abstract][Full Text] [Related]
26. A possible role of p73 on the modulation of p53 level through MDM2.
Wang XQ; Ongkeko WM; Lau AW; Leung KM; Poon RY
Cancer Res; 2001 Feb; 61(4):1598-603. PubMed ID: 11245471
[TBL] [Abstract][Full Text] [Related]
27. The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas.
Calogero A; Arcella A; De Gregorio G; Porcellini A; Mercola D; Liu C; Lombari V; Zani M; Giannini G; Gagliardi FM; Caruso R; Gulino A; Frati L; Ragona G
Clin Cancer Res; 2001 Sep; 7(9):2788-96. PubMed ID: 11555594
[TBL] [Abstract][Full Text] [Related]
28. Promoter specificity and stability control of the p53-related protein p73.
Lee CW; La Thangue NB
Oncogene; 1999 Jul; 18(29):4171-81. PubMed ID: 10435630
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of MDM-2 mRNA and mutation of the p53 tumor suppressor gene in bladder carcinoma cell lines.
Cheng YT; Li YL; Wu JD; Long SB; Tzai TS; Tzeng CC; Lai MD
Mol Carcinog; 1995 Jul; 13(3):173-81. PubMed ID: 7619220
[TBL] [Abstract][Full Text] [Related]
30. Genetic alterations of p16INK4a and p14ARF genes in human bladder cancer.
Chang LL; Yeh WT; Yang SY; Wu WJ; Huang CH
J Urol; 2003 Aug; 170(2 Pt 1):595-600. PubMed ID: 12853838
[TBL] [Abstract][Full Text] [Related]
31. MDM2 mRNA expression in the p53 pathway may predict the potential of invasion and liver metastasis in colorectal cancer.
Kondo I; Iida S; Takagi Y; Sugihara K
Dis Colon Rectum; 2008 Sep; 51(9):1395-402. PubMed ID: 18607552
[TBL] [Abstract][Full Text] [Related]
32. P14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2.
Xirodimas DP; Chisholm J; Desterro JM; Lane DP; Hay RT
FEBS Lett; 2002 Sep; 528(1-3):207-11. PubMed ID: 12297306
[TBL] [Abstract][Full Text] [Related]
33. p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53.
Lindström MS; Klangby U; Wiman KG
Oncogene; 2001 Apr; 20(17):2171-7. PubMed ID: 11360201
[TBL] [Abstract][Full Text] [Related]
34. Loss of p63 expression is associated with tumor progression in bladder cancer.
Urist MJ; Di Como CJ; Lu ML; Charytonowicz E; Verbel D; Crum CP; Ince TA; McKeon FD; Cordon-Cardo C
Am J Pathol; 2002 Oct; 161(4):1199-206. PubMed ID: 12368193
[TBL] [Abstract][Full Text] [Related]
35. Deregulation of p73 isoform equilibrium in benign prostate hyperplasia and prostate cancer.
Arvanitis DA; Lianos E; Soulitzis N; Delakas D; Spandidos DA
Oncol Rep; 2004 Nov; 12(5):1131-7. PubMed ID: 15492805
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder.
Uchida T; Minei S; Gao JP; Wang C; Satoh T; Baba S
Oncol Rep; 2002; 9(2):253-9. PubMed ID: 11836589
[TBL] [Abstract][Full Text] [Related]
37. Expression of the p14ARF tumor suppressor predicts survival in acute myeloid leukemia.
Müller-Tidow C; Metzelder SK; Buerger H; Packeisen J; Ganser A; Heil G; Kügler K; Adigüzel G; Schwäble J; Steffen B; Ludwig WD; Heinecke A; Büchner T; Berdel WE; Serve H
Leukemia; 2004 Apr; 18(4):720-6. PubMed ID: 14973498
[TBL] [Abstract][Full Text] [Related]
38. p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2.
Esteller M; Cordon-Cardo C; Corn PG; Meltzer SJ; Pohar KS; Watkins DN; Capella G; Peinado MA; Matias-Guiu X; Prat J; Baylin SB; Herman JG
Cancer Res; 2001 Apr; 61(7):2816-21. PubMed ID: 11306450
[TBL] [Abstract][Full Text] [Related]
39. Genomic organisation of the human MDM2 oncogene and relationship to its alternatively spliced mRNAs.
Liang H; Atkins H; Abdel-Fattah R; Jones SN; Lunec J
Gene; 2004 Sep; 338(2):217-23. PubMed ID: 15315825
[TBL] [Abstract][Full Text] [Related]
40. p73 transcriptional activity increases upon cooperation between its spliced forms.
Alarcon-Vargas D; Fuchs SY; Deb S; Ronai Z
Oncogene; 2000 Feb; 19(6):831-5. PubMed ID: 10698502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
